ncRNA AND USES THEREOF
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.
1 .- 272 . (canceled)
273 . A system for analyzing a cancer, comprising:
a. a probe set comprising a plurality of probes, wherein the plurality of probes comprises a sequence that hybridizes to at least a portion of one or more target molecules selected from the group comprising PCAT, SChLAP-1, TU0011194, TU0019356, TU0024146, TU0009141, TU0062051, TU0021861, M41, ENST-75, and SEQ ID NOs: 1-9; and
b. a computer model or algorithm for analyzing an expression level and/or expression profile of a target molecule hybridized to the probe in a sample from a subject suffering from a cancer.
274 . The system claim 273 , wherein PCAT is selected from the group comprising PCAT1, PCAT2, PCAT3, PCAT4, PCAT5, PCAT6, PCAT7, PCAT8, PCAT9, PCAT10, PCAT11, PCAT12, PCAT13, PCAT14, PCAT15, PCAT16, PCAT17, PCAT18, PCAT19, PCAT20, PCAT21, PCAT22, PCAT23, PCAT24, PCAT25, PCAT26, PCAT27, PCAT28, PCAT29, PCAT30, PCAT31, PCAT32, PCAT33, PCAT34, PCAT35, PCAT36, PCAT37, PCAT38, PCAT39, PCAT40, PCAT41, PCAT42, PCAT43, PCAT44, PCAT45, PCAT46, PCAT47, PCAT48, PCAT49, PCAT50, PCAT51, PCAT52, PCAT53, PCAT54, PCAT55, PCAT56, PCAT57, PCAT58, PCAT59, PCAT60, PCAT61, PCAT62, PCAT63, PCAT64, PCAT65, PCAT66, PCAT67, PCAT68, PCAT69, PCAT70, PCAT71, PCAT72, PCAT73, PCAT74, PCAT75, PCAT76, PCAT77, PCAT78, PCAT79, PCAT80, PCAT81, PCAT82, PCAT83, PCAT84, PCAT85, PCAT86, PCAT87, PCAT88, PCAT89, PCAT90, PCAT91, PCAT92, PCAT93, PCAT94, PCAT95, PCAT96, PCAT97, PCAT98, PCAT99, PCAT100, PCAT101, PCAT102, PCAT103, PCAT104, PCAT105, PCAT106, PCAT107, PCAT108, PCAT109, PCAT110, PCAT111, PCAT112, PCAT113, PCAT114, PCAT115, PCAT116, PCAT117, PCAT118, PCAT119, PCAT120, and PCAT121.
275 . The system of claim 273 , further comprising an electronic memory for capturing and storing an expression profile.
276 . The system of claim 273 , further comprising a computer-processing device, optionally connected to a computer network.
277 . The system of claim 276 , further comprising a software module executed by the computer-processing device to analyze an expression profile.
278 . The system of claim 276 , further comprising a software module executed by the computer-processing device to compare the expression profile to a standard or control.
279 . The system of claim 276 , further comprising a software module executed by the computer-processing device to determine the expression level of the target.
280 . The system of claim 276 , further comprising a software module executed by the computer-processing device to transmit an analysis of the expression profile to the subject or a medical professional treating the subject.
281 . The system of claim 276 , further comprising a software module executed by the computer-processing device to transmit a diagnosis or prognosis to the subject or a medical professional treating the subject.
282 . The system of claim 273 , further comprising a machine to isolate the target or the probe from the sample, a machine to sequence the target or the probe, and/or a machine to amplify the target or the probe.
283 . The system of claim 273 , wherein the plurality of probes comprises a sequence that hybridizes to at least a portion of two or more target molecules selected from the group comprising PCAT, SChLAP-1, TU0011194, TU0019356, TU0024146, TU0009141, TU0062051, TU0021861, M41, ENST-75, and SEQ ID NOs: 1-9.
284 . The system of claim 273 , wherein the cancer is selected from the group comprising prostate, lung, breast, and pancreatic cancer.
285 . The system of claim 273 , wherein the plurality of probes comprises a sequence that hybridizes to at least a portion of one or more target molecules selected from the group comprising and SEQ ID NOs: 1-9, PCAT1, PCAT14, PCAT43, PCAT 109, and SChLAP-1.
286 . The system of claim 285 , wherein the cancer is a prostate cancer.
287 . The system of claim 273 , wherein the plurality of probes comprises a sequence that hybridizes to at least a portion of one or more target molecules selected from the group comprising M41 and ENST-75.
288 . The system of claim 287 , wherein the cancer is a lung cancer.
289 . The system of claim 273 , wherein the plurality of probes comprises a sequence that hybridizes to at least a portion of one or more target molecules selected from the group comprising TU0011194, TU0019356 and TU0024146.
290 . The system of claim 288 , wherein the cancer is a breast cancer or prostate.
291 . The system of claim 273 , wherein the plurality of probes is attached to one or more solid supports.
292 . The system of claim 291 , wherein the one or more solid supports is a bead, array, microarray, well, plate, chip, or a combination thereof.